XTANDI\u00ae is the commercial brand name of Enzalutamide Soft Capsules, an orally active, second-generation non-steroidal androgen receptor inhibitor developed by Astellas Pharma. It exerts anti-tumor activity by competitively inhibiting androgen binding to the androgen receptor, blocking nuclear translocation of the receptor, and suppressing DNA binding and coactivator recruitment, thereby inhibiting the proliferation of prostate cancer cells.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy XTANDI (Enzalutamide Soft Capsules)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" XTANDI\u00ae is the commercial brand name of Enzalutamide Soft Capsules, an orally active, second-generation non-steroidal androgen receptor inhibitor developed by Astellas Pharma. It exerts anti-tumor activity by competitively inhibiting androgen binding to the androgen receptor, blocking nuclear translocation of the receptor, and suppressing DNA binding and coactivator recruitment, thereby inhibiting the proliferation of prostate cancer […]<\/p>\n","protected":false},"author":4,"featured_media":3431,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men;
Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men who are at high risk of developing metastatic disease;
Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).<\/p>\n\n\n\n
Common adverse reactions: Fatigue, asthenia, hot flashes, hypertension, diarrhea, headache, decreased appetite, joint pain, dizziness, and insomnia.
Laboratory abnormalities: Neutropenia, thrombocytopenia, and elevated transaminases.
Severe but manageable risks: Seizures, posterior reversible encephalopathy syndrome (PRES), falls and fractures, and ischemic heart disease.<\/p>\n\n\n\n
XTANDI\u00ae (Enzalutamide Soft Capsules, 40mg) was officially approved for marketing in China in 2019. It is currently a prescription drug included in China\u2019s Category B medical insurance.<\/p>\n\n\n\n